Citizens JMP lowered the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $42 and keeps an Outperform rating on the shares. Viridian reported Q1 results and reiterated that it remains on track to submit the veligrotug Biologics License Application for thyroid eye disease in the second half of 2025, the analyst tells investors in a research note. Additional clinical catalysts remain on track, and the company is well-funded to execute on broad development activities, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Reports Q1 2025 Progress and Financials
- Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating
- Buy Rating for Viridian Therapeutics: Strong Pipeline and Financial Position Drive Strategic Advancements
- Viridian Therapeutics: Promising Outlook with Strong Pipeline and Regulatory Progress
- Viridian Therapeutics, Inc. (VRDN) Q1 Earnings Cheat Sheet